Molnupiravir, a repurposed flu antiviral with a poor history, delivers in a pivotal study in Covid-19 outpatients.
With no deaths in the treatment arm, Blaze-1 could allow emergency authorisation of the doublet antibody therapy.
Like Lilly, Regeneron reckons its antibodies can be used to prevent Covid-19 infection. Now comes the hard part.
An NIAID-sponsored study of a Lilly antibody has been paused for possible toxicity, prompting speculation over the cause of the problem.
LY-CoV555 shows promising signs for the antibody approach, with Regeneron not far behind.